ArticlePloS one2014
A computerized prediction model of hazardous inflammatory platelet transfusion outcomes.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- In Vitro Modeling of Age-Associated Lipid Mediator's Impact on Vascular Biology Following Platelet Concentrate Transfusion.Aging cell · 2026Article
- The composition of single-donor apheresis platelet concentrates is influenced by the age of the donor.Scientific reports · 2025Article
- Transfusion-Related Acute Lung Injury: from Mechanistic Insights to Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Identification of new bioactive molecules in platelet preparation, storage, and transfusion reactions for improved transfusion management.Scientific reports · 2024Article
- Lowering platelet-count threshold for transfusion in preterm neonates decreases the number of transfusions without increasing severe hemorrhage events.European journal of pediatrics · 2024Article
- Machine learning in transfusion medicine: A scoping review.Transfusion · 2024Article
- Lipidomic analysis of differently prepared platelet concentrates in additive solution during storage.Blood transfusion = Trasfusione del sangue · 2023Article
- Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion.Frontiers in immunology · 2023Article
- Protein Concentrations in Stored Pooled Platelet Concentrates Treated with Pathogen Inactivation by Amotosalen Plus Ultraviolet a Illumination.Pathogens (Basel, Switzerland) · 2022Article
- Platelets as Key Factors in Inflammation: Focus on CD40L/CD40.Frontiers in immunology · 2022Review
- Platelet Inflammatory Response to Stress.Frontiers in immunology · 2019Review
- Leucocyte cytokines dominate platelet cytokines overtime in non-leucoreduced platelet components.Blood transfusion = Trasfusione del sangue · 2018Article
- Levels of human platelet-derived soluble CD40 ligand depend on haplotypes of CD40LG-CD40-ITGA2.Scientific reports · 2016Article
- Improving platelet transfusion safety: biomedical and technical considerations.Blood transfusion = Trasfusione del sangue · 2016Review
- Transfusion as an Inflammation Hit: Knowns and Unknowns.Frontiers in immunology · 2016Review
- Platelets and infections - complex interactions with bacteria.Frontiers in immunology · 2015Review
- The signaling role of CD40 ligand in platelet biology and in platelet component transfusion.International journal of molecular sciences · 2014Review
- Are polymorphisms of the immunoregulatory factor CD40LG implicated in acute transfusion reactions?Scientific reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet component (PC) transfusion leads occasionally to inflammatory hazards. Certain BRMs that are secreted by the platelets themselves during storage may have some responsibility. METHODOLOGY/PRINCIPAL
findingsFirst, we identified non-stochastic arrangements of platelet-secreted BRMs in platelet components that led to acute transfusion reactions (ATRs). These data provide formal clinical evidence that platelets generate secretion profiles under both sterile activation and pathological conditions. We next aimed to predict the risk of hazardous outcomes by establishing statistical models based on the associations of BRMs within the incriminated platelet components and using decision trees. We investigated a large (n = 65) series of ATRs after platelet component transfusions reported through a very homogenous system at one university hospital. Herein, we used a combination of clinical observations, ex vivo and in vitro investigations, and mathematical modeling systems. We calculated the statistical association of a large variety (n = 17) of cytokines, chemokines, and physiologically likely factors with acute inflammatory potential in patients presenting with severe hazards. We then generated an accident prediction model that proved to be dependent on the level (amount) of a given cytokine-like platelet product within the indicated component, e.g., soluble CD40-ligand (>289.5 pg/109 platelets), or the presence of another secreted factor (IL-13, >0). We further modeled the risk of the patient presenting either a febrile non-hemolytic transfusion reaction or an atypical allergic transfusion reaction, depending on the amount of the chemokine MIP-1α (<20.4 or >20.4 pg/109 platelets, respectively). CONCLUSIONS/SIGNIFICANCE: This allows the modeling of a policy of risk prevention for severe inflammatory outcomes in PC transfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.